David Scott Jones - Jun 22, 2021 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jun 22, 2021
Transactions value $
$0
Form type
4
Date filed
6/23/2021, 05:28 PM
Next filing
Nov 3, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +14.9K +362.97% $0.00 19K Jun 22, 2021 Common Stock 14.9K $0.00 Direct F1
transaction EYPT Stock Option (Right to Buy) Award $0 +60.3K $0.00 60.3K Jun 22, 2021 Common Stock 60.3K $13.13 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
F2 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.